Balancing patient value and payer cost in hematologic malignancies: can it be done?
作者信息
Allen Pamela B, Flowers Christopher R
机构信息
a Department of Hematology and Medical Oncology , Winship Cancer Institute, Emory University School of Medicine , Atlanta , GA , USA.
出版信息
Expert Rev Pharmacoecon Outcomes Res. 2018 Apr;18(2):123-126. doi: 10.1080/14737167.2018.1444478. Epub 2018 Mar 13.
Abstract
摘要
相似文献
1
Balancing patient value and payer cost in hematologic malignancies: can it be done?在血液系统恶性肿瘤中平衡患者价值与支付方成本：这能做到吗？
Expert Rev Pharmacoecon Outcomes Res. 2018 Apr;18(2):123-126. doi: 10.1080/14737167.2018.1444478. Epub 2018 Mar 13.
2
Considerations for Cost-effectiveness Analysis of Curative Pediatric Therapies.儿科治疗性疗法成本效益分析的考量因素
JAMA Pediatr. 2018 May 1;172(5):409-410. doi: 10.1001/jamapediatrics.2018.0049.
3
Novel and Expanded Oncology Drug Approvals of 2016-PART 2: New Options in the Management of Hematologic Malignancies.2016年新型及扩展型肿瘤药物获批情况——第二部分：血液系统恶性肿瘤治疗新选择
Oncology (Williston Park). 2017 Feb 15;31(2):138-46.
4
Monthly and Median Costs of Cancer Drugs at the Time of FDA Approval 1965-2016.1965年至2016年美国食品药品监督管理局批准时癌症药物的月度成本和中位数成本。
J Natl Cancer Inst. 2017 Aug 1;109(8). doi: 10.1093/jnci/djx173.
5
Meaningful endpoints for therapies approved for hematologic malignancies.已获批用于血液系统恶性肿瘤治疗的有意义的终点指标。
Cancer. 2017 May 15;123(10):1689-1694. doi: 10.1002/cncr.30622. Epub 2017 Feb 21.
6
Canadian Regulatory and Health Technology Assessment for Malignant Hematology and Oncology Indications Compared With the US Food and Drug Administration Accelerated Approval Program.加拿大恶性血液病和肿瘤学适应证的监管和卫生技术评估与美国食品和药物管理局加速批准计划的比较。
JAMA Netw Open. 2021 Aug 2;4(8):e2120301. doi: 10.1001/jamanetworkopen.2021.20301.
7
How should we assess the clinical and cost effectiveness of histology independent cancer drugs?我们应如何评估不依赖组织学的癌症药物的临床和成本效益？
BMJ. 2020 Jan 2;368:l6435. doi: 10.1136/bmj.l6435.
8
9
Rollout of high-priced cell and gene therapies forces payer rethink.高价细胞和基因疗法的推出迫使支付方重新思考。
Nat Biotechnol. 2018 Apr 5;36(4):291-292. doi: 10.1038/nbt0418-291a.
10
[Clinical value of interferon-alpha in the treatment of malignant hematologic diseases].α干扰素在恶性血液病治疗中的临床价值
Presse Med. 1997 May 31;26(18):857-9.
引用本文的文献
1
Real-World Health Care Resource Use and Costs Among Patients With Chronic Lymphocytic Leukemia Treated With Venetoclax-Based and Bruton Tyrosine Kinase Inhibitor-Based Regimens in the Second-Line Setting.在二线治疗环境中，接受 Venetoclax 为基础和 Bruton 酪氨酸激酶抑制剂为基础方案治疗的慢性淋巴细胞白血病患者的真实世界卫生保健资源利用和成本。
JCO Oncol Pract. 2024 Aug;20(8):1132-1139. doi: 10.1200/OP.23.00630. Epub 2024 Apr 16.
2
Trends in Clinical Benefits and Costs of Novel Therapeutics in AML: at What Price Does Progress Come?新型治疗药物在 AML 中的临床获益和成本趋势：进展需要付出多大代价？
Curr Hematol Malig Rep. 2019 Jun;14(3):171-178. doi: 10.1007/s11899-019-00510-2.
本文引用的文献
1
Exploring the potential cost-effectiveness of precision medicine treatment strategies for diffuse large B-cell lymphoma.探索弥漫性大B细胞淋巴瘤精准医学治疗策略的潜在成本效益。
Leuk Lymphoma. 2018 Jul;59(7):1700-1709. doi: 10.1080/10428194.2017.1390230. Epub 2017 Oct 25.
2
The Search for Surrogate Endpoints in Trials in Diffuse Large B-Cell Lymphoma: The Surrogate Endpoints for Aggressive Lymphoma Project.弥漫性大 B 细胞淋巴瘤临床试验中替代终点的探索：侵袭性淋巴瘤项目的替代终点。
Oncologist. 2017 Dec;22(12):1415-1418. doi: 10.1634/theoncologist.2017-0177. Epub 2017 Aug 10.
3
Choosing Wisely in Oncology: Are We Ready For Value-Based Care?肿瘤学中的明智选择：我们准备好迎接基于价值的医疗了吗？
J Oncol Pract. 2017 Nov;13(11):e935-e943. doi: 10.1200/JOP.2016.019281. Epub 2017 Aug 7.
4
The Cost Impact of Lenalidomide for Newly Diagnosed Multiple Myeloma in the EU5.来那度胺对欧盟五国新诊断多发性骨髓瘤的成本影响
Oncol Ther. 2017;5(1):31-40. doi: 10.1007/s40487-016-0037-8. Epub 2017 Jan 3.
5
Improved survival in multiple myeloma, with a diminishing racial gap and a widening socioeconomic status gap over three decades.多发性骨髓瘤患者的生存率有所提高，在三十年的时间里，种族差距逐渐缩小，社会经济地位差距不断扩大。
Leuk Lymphoma. 2018 Jan;59(1):49-58. doi: 10.1080/10428194.2017.1335398. Epub 2017 Jun 9.
6
Cost-related medication nonadherence among adolescent and young adult cancer survivors.青少年和青年癌症幸存者中与费用相关的药物治疗不依从情况。
Cancer. 2017 Jul 15;123(14):2726-2734. doi: 10.1002/cncr.30648. Epub 2017 May 23.
7
Measuring the Value of New Drugs: Validity and Reliability of 4 Value Assessment Frameworks in the Oncology Setting.衡量新药的价值：4 种肿瘤学评估框架的有效性和可靠性。
J Manag Care Spec Pharm. 2017 Jun;23(6-a Suppl):S34-S48. doi: 10.18553/jmcp.2017.23.6-a.s34.
8
Cancer Statistics, 2017.《2017 年癌症统计》
CA Cancer J Clin. 2017 Jan;67(1):7-30. doi: 10.3322/caac.21387. Epub 2017 Jan 5.
9
Trends in overall survival and costs of multiple myeloma, 2000-2014.2000 - 2014年多发性骨髓瘤的总生存率和成本趋势。
Leukemia. 2017 Sep;31(9):1915-1921. doi: 10.1038/leu.2016.380. Epub 2016 Dec 23.
10
Factors Associated With Tyrosine Kinase Inhibitor Initiation and Adherence Among Medicare Beneficiaries With Chronic Myeloid Leukemia.慢性粒细胞白血病医疗保险受益人中酪氨酸激酶抑制剂起始治疗和依从性的相关因素
J Clin Oncol. 2016 Dec 20;34(36):4323-4328. doi: 10.1200/JCO.2016.67.4184. Epub 2016 Oct 31.
Zotero 插件